JOHN KETA: Open Payments
NPI 1144245804 · TROY, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$666 in 38 payments from 7 companies in 2025. Trend: 2023 $120 · 2024 $96 · 2025 $666
Food & beverage: $666
| Company | Payments | Amount |
|---|---|---|
| Verona Pharma, Inc. | 14 | $203 |
| GlaxoSmithKline, LLC. | 9 | $140 |
| Insmed, Inc. | 8 | $140 |
| Amgen Inc. | 3 | $74 |
| Actelion Pharmaceuticals US, Inc. | 1 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $44 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
Products named: Ohtuvayre, Arikayce, TEZSPIRE, NUCALA, OPSUMIT, TRELEGY ELLIPTA, AREXVY, FASENRA.
Industry payments across MI — which companies pay providers there.
